NCT01527929View on ClinicalTrials.gov

Pharmacokinetics and Safety Study of Cabazitaxel in Cancer Patients With Renal Impairment

PHASE1CompletedINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

April 30, 2012

Primary Completion Date

November 30, 2013

Study Completion Date

November 30, 2013

Conditions
Neoplasm Malignant
Interventions
DRUG

Cabazitaxel XRP6258

Pharmaceutical form: solution for infusion Route of administration: intravenous

Trial Locations (7)

1200

Investigational Site Number 056002, Brussels

9000

Investigational Site Number 056001, Ghent

20133

Investigational Site Number 380001, Milan

3075 EA

Investigational Site Number 528001, Rotterdam

3584 CX

Investigational Site Number 528002, Utrecht

08035

Investigational Site Number 724001, Barcelona

CB2 2QQ

Investigational Site Number 826001, Cambridge

Sponsors

Lead Sponsor

Sanofi
All Listed Sponsors
lead

Sanofi

INDUSTRY

NCT01527929 - Pharmacokinetics and Safety Study of Cabazitaxel in Cancer Patients With Renal Impairment | Biotech Hunter | Biotech Hunter